Identification and pharmaceutical evaluation of novel frog skin-derived serine proteinase inhibitor peptide–PE-BBI (Pelophylax esculentus Bowman-Birk inhibitor) for the potential treatment of cancer by Lyu, Peng et al.
Identification and pharmaceutical evaluation of novel frog skin-derived
serine proteinase inhibitor peptide–PE-BBI (Pelophylax esculentus
Bowman-Birk inhibitor) for the potential treatment of cancer
Lyu, P., Ge, L., Ma, R., Wei, R., McCrudden, C., Chen, T., ... Kwok, H. F. (2018). Identification and
pharmaceutical evaluation of novel frog skin-derived serine proteinase inhibitor peptide–PE-BBI (Pelophylax
esculentus Bowman-Birk inhibitor) for the potential treatment of cancer. Scientific Reports, 8, [14502].
https://doi.org/10.1038/s41598-018-32947-5
Published in:
Scientific Reports
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2018 the authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:05. Apr. 2019
1SCieNTiFiC RepoRts |  (2018) 8:14502  | DOI:10.1038/s41598-018-32947-5
www.nature.com/scientificreports
Identification and pharmaceutical 
evaluation of novel frog skin-
derived serine proteinase inhibitor 
peptide–PE-BBI (Pelophylax 
esculentus Bowman-Birk inhibitor) 
for the potential treatment of 
cancer
Peng Lyu1, Lilin Ge1,2, Rui Ma1, Ran Wei1, Cian M. McCrudden3, Tianbao Chen3, Chris Shaw3 & 
Hang Fai Kwok  1
Amphibian venom-derived peptides have high potential in the field of anticancer drug discovery. We 
have isolated a novel Bowman-Birk proteinase inhibitor (BBI)-type peptide from the skin secretion 
of Pelophylax esculentus (PE) named PE-BBI, and evaluated its bio-functions and anti-cancer activity 
in vitro. PE-BBI is a heptadecapeptide with C-terminal amidation. The mRNA sequence and primary 
structure of PE-BBI were identified using RT-PCR and LC/MS, respectively. A trypsin inhibitory assay 
was used to characterize the serine proteinase inhibitory activity of synthetic PE-BBI. PE-BBI’s 
myotropic activity was analyzed using isolated rat bladder and rat-tail artery smooth muscle tissues, 
and the anti-cancer ability of PE-BBI using human colorectal cancer cells. PE-BBI’s mechanism of 
action was investigated using Discovery studio software. PE-BBI showed trypsin inhibitory activity 
(Ki = 310 ± 72 nM), strong myotropic activity, and cytotoxicity that were specific to cancer cells, and 
no side effect to normal epithelial cells. The docking stimulation showed that PE-BBI had high affinity 
to several members of human kallikrein related peptidase (KLK) family. This finding helps to enrich 
our understanding of BBI peptides’ mode of action. Moreover, the data presented here validates frog 
secretions as sources of potential novel proteinase inhibitors for cancer treatment.
The serine protease inhibitor family is one of the most widely distributed natural proteinase inhibitors. Serine 
protease inhibitors are able to regulate certain proteases participated in many human physiological and patholog-
ical processes, such as peptide hormone release, digestion, host defence, blood coagulation, disease progression, 
hypertension, muscular dystrophy, cancer, acquired immunodeficiency syndrome (AIDS), and microbial infec-
tions1–4. Serine proteinase inhibitors are also crucial in proteolytic activity disorder processes, which may cause 
a disruption in physiological processes, homeostatic balance, the expanding of tumour cells and degenerative 
diseases5–7. Understanding the roles serine protease inhibitors play in diseases may offer opportunities for devel-
opment of therapeutic agents8. Proteinase inhibitors have been classified into more than 10 families, based on 
their structural features, including Kunitz, Kazal, and Bowman-Birk proteinase inhibitor (BBI) motifs9.
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The BBI inhibitor family is a typical serine proteinase family, is commonly/largely found in the seeds of legu-
minous plants, and possesses strong trypsin and chymotrypsin inhibitory activities10. BBIs inhibit their targeted 
enzymes by a substrate-like manner through exposing their canonical conformation binding loop11–14. The two 
highly conserved canonical disulphide loops of BBI are the crucial structure for their trypsin and chymotrypsin 
inhibitory activities. In each loop, a hyper-exposed amino acid residue (lysine or arginine) called P1 residue 
(named by Schechter and Berger15) interacts with the active site of the enzyme, which is the most comment 
inhibitor-enzyme contacts and is responsible for inhibitor’s specificity16. Activated BBI can specifically bind to its 
correlated enzyme in a substrate-like manner, after which, the disulphide loop forms a stable complex with the 
active site of the proteinase9,17. The studies of BBIs have attracted increasing interest in the past decade due to their 
unique multiple functions. Within these studies, the functions of BBIs are ranging from pest control in transgenic 
plants, to the clinical aspect including anti-cancer, inflammatory, and allergic disorders18. In April 1992, BBI con-
centrate (BBIC), a soybean extract rich in BBI, have achieved Investigational New Drug status from the US Food 
and Drug Administration (FDA)19. BG-4, a BBI-type peptide was identified that has apoptosis-inducing activity 
in HCT-116 and HT-29 human colon cancer cell lines20. Recently, SFTI-1 (Sunflower trypsin inhibitor 1) and its 
structural modified variants showed specifically inhibition of kallikrein related peptidase (KLK) family. So far, 
some members of kallikrein family have been considered to be the diagnostic/prognostic biomarkers in different 
cancer types, including breast, ovarian, prostate and testicular carcinomas21,22. Furthermore, overexpression of 
KLK6, KLK8, and KLK10 were reported in colon cancer (CRC)23. Ogawa24 also further confirmed KLK6 mRNA 
overexpression leads to a poor prognosis in CRC patient cohorts.
Increasing evidence implies that BBI protease inhibitors were capable to inhibit the activity of KLK protein 
family, which are poor prognosis biomarkers for several carcinomas and other diseases reported in many stud-
ies21–24. As we know, cancer proliferation, migration, and invasion are complex pathological processes in which 
proteolytic enzymes were involved. As the expression and activity of these proteolytic enzymes have a strong cor-
relation with the invasiveness and metastasis of cancer cells25, BBIs are being investigated as potential anti-colon 
cancer therapy. Here, we report the BBI-like peptide with anticancer activity found in frog skin secretion. PE-BBI 
(Pelophylax esculentus Bowman-Birk inhibitor) appeared to be a heptadecapeptide with C-terminal amidation. 
The molecular weight of PE-BBI (1.8 kDa) is much smaller than the canonical BBI protein (8~16 kDa) from legu-
mina. PE-BBI contains the conserved disulphide loop between Cys6 and Cys16, which is homologous to the much 
bigger BBI family members. The synthetic replicates of PE-BBI were characterized by multiple organ-bath based 
ex vivo rat smooth muscle tissue probes and in vitro anticancer activity screening. We showed that PE-BBI is able 
to inhibit proliferation of several colon cancer cells without any obvious cytotoxicity to normal epithelial cells. 
These results suggested that PE-BBI might be a potential anticancer peptide, resultant of its protease inhibitory 
effects.
Results
Structural Characterisation of PE-BBI. Skin secretions from Pelophylax esculentus, were fractionated by 
RP-HPLC using a C5 column (Fig. 1A). Samples of all 240 chromatographic fractions were subjected to MS/MS 
fragmentation. All of the fractions were subjected to a trypsin inhibition screening assay. Fraction #94 (arrowed) 
displayed strong trypsin inhibitory activity. Then the MS/MS fragmentation sequencing was applied to clarify the 
primary sequence of the mature peptide, PE-BBI (Fig. 1B).
Molecular Cloning of PE-BBI Biosynthetic Precursor. The precursor cDNA open reading frame was 
obtained by two steps in molecular cloning. Briefly, the 3′-RACE reactions employed a nested universal primer 
(NUP) (supplied with the kit) and a sense primer (S: 5′-GGNGCNYTNAARGGNTGYTGGAGALKGCWT-3
′) that is complementary to the N-terminal amino acid sequence. The product of 3′-RACE was further purified, 
then cloned using a pGEM-T vector system (Promega Corporation). Finally, the sample was sequenced by ABI 
3100 sequencer. The specific antisense primer (AS: 5′-CCACATCAGATGACTTCCTCATCAT-3′), targeted to a 
conserved site within the 3′-non translated region of peptide precursor-encoding cDNA, was designed based on 
3′-RACE products. Followed the same protocol, 5′-RACE was carried out. The full-length coding sequence was 
showed in Fig. 1C. The amino acid sequence and stick representation of PE-BBI was shown in Fig. 1D,E.
Peptide Synthesis. The synthetic PE-BBI was detected by HPLC system in Fig. 1F. The purity of synthetic 
PE-BBI was higher than 95%. Subsequently, the synthetic replicates of PE-BBI was detected by MALDI-ToF. Three 
peaks were observed in Fig. 1G, 1812.907 Da for PE-BBI with intramolecular disulphide bridge, 1834.226 Da for 
PE-BBI with Sodium+ and 3623.609 Da for PE-BBI dimer, which generated from the intermolecular disulphide 
bond, the concentration of PE-BBI dimer was less than 2%. The synthetic replicates were applied in the following 
bio-assays.
Trypsin Inhibitory Activity of PE-BBI. Synthetic replicates of PE-BBI was serially quantified for trypsin 
inhibitory activity in the range of 0.1–100 µM. PE-BBI showed a competitive reversible trypsin inhibitory activity. 
The dose-dependent hydrolysis of the fluorogenic substrates curve of PE-BBI were shown in Fig. 2A. The initial 
rates (vi) were calculated from Fig. 2A, and the initial rates were used to calculate the inhibition constants (Ki) 
value by using ‘Morrison plots’ (Fig. 2B)26. Compared with some other BBI-type peptides such as HV-BBI and 
pLR-HL, PE-BBI was found to behave as a moderately potent trypsin inhibitor with a Ki value of 310 ± 72 nM. To 
further confirm the binding model between PE-BBI and bovine trypsin protease, we applied ZDock to simulate 
the binding model. From the simulation results, we can find that the active site (Lys9) of PE-BBI inserts into the 
reaction site (His58, Asp102, and Ser195) of bovine trypsin proteinase, thus blocking trypsin’s proteolytic activity. 
The simulation result shows PE-BBI might affect trypsin proteinase in the same way as reported BBI inhibitor 
peptide(s)/protein(s) (Fig. 2C).
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Myotropic Effects of PE-BBI. Synthetic PE-BBI was found to be active in the rat tail artery and the blad-
der smooth muscle preparations (Fig. 3A,B). In the preparations of rat bladder smooth muscle, PE-BBI showed 
a dose-dependent contraction with an EC50 value of 14.25 nM (Fig. 3A). In preparations of rat artery, PE-BBI 
evoked a dose-dependent relaxation with an EC50 value of 8.79 nM (Fig. 3B).
Antimicrobial Effects of PE-BBI. Antimicrobial activity of synthetic PE-BBI was assessed by determi-
nation of MIC assays using E. coli, S. aureus, and C. albicans. In this assay, PE-BBI didn’t show any obviously 
antibacterial activity even in the highest concentration (512 μM). The results illustrated that PE-BBI did not have 
antibacterial activity against bacterial and fungi (Data not showed).
Anti-cancer Activity of PE-BBI. Previous studies supported the idea of the potential therapeutic use of 
BBI-type peptides as the anticancer therapy against human colon cancer. Thus, four human cancer cell lines 
including DLD-1, DKS8, HCT116, and HKE3 were used to examine the anti-proliferative effects of PE-BBI. 
Human colon endothelial cell line (FHC) was used to evaluate the inherent cytotoxicity of PE-BBI against normal 
human cells. PE-BBI showed selective cytotoxicity against the four different cancer cell lines and almost no cyto-
toxicity against FHC cells (Fig. 4A–E). The IC50 values against four cancer cell lines after 24 h incubation, were 
50.1 µM, 9.8 µM, 35.4 µM, 50.2 µM, respectively. Meanwhile, PE-BBI didn’t show any cytotoxicity against human 
normal endothelial cell lines FHC.
Molecular Docking Analysis Results of PE-BBI. Molecular docking study was performed by BIOVIA 
Discovery Studio software to determine the putative docking of PE-BBI with KLKs. The visualized report of 
Figure 1. (A) Reverse phase HPLC chromatogram of lyophilised Pelophylax esculentus skin secretion, the 
arrow indicates the peak of PE-BBI. (B) Table of predicted mass of PE-BBI fragmentations with singly and 
doubly charged. The fractions detected by MS/MS were present in red and blue. (C) Nucleotide sequence of 
cDNA encoding the PE-BBI clone from Pelophylax esculentus. The putative signal peptide was indicated by 
double-underline. The mature peptide was labelled by single-underline. The stop codon (asterisk) was also 
indicated. (D) Schematic depiction of PE-BBI peptide. (E) Structure of PE-BBI in stick representation. The 
active site Lys9 was labelled (Yellow) and the intramolecular disulphide bond was present between Cys6 and 
Cys16 (Orange bond). (F) HPLC results of synthetic PE-BBI. (G) MALDI-ToF result of synthetic PE-BBI.
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simulation was shown in Fig. 5. ZDock module of Discovery Studio was used for docking and scoring; then 
RDock was applied to optimize the binding results. The models optimized by RDock module were performed 
in Fig. 5A–D, respectively. The docking analysis revealed that PE-BBI is highly likely binding to the active site of 
KLKs. These results further confirmed our prediction of peptide binding mechanism. PE-BBI had high affinity to 
certain members of human KLKs protein, which could induce the inhibition of KLKs. Consequently, the inhibi-
tion of the KLKS would in turn also had implications for related cancer pathology processes.
Discussion
Amphibian skin secretions have long been known as complex cocktails of bioactive peptides. Several differ-
ent classes of serine protease inhibitor peptides have been isolated and identified from frog skin secretions, 
including Bowman-Birk-like trypsin inhibitor peptides, which are classified according to their primary struc-
ture9. Skin secretion proteinase inhibitors are believed to be widespread in Rana frog species and their pri-
mary structure-based modifications can produce a series of analogues (shown in Fig. 6), such as HV-BBI and 
pLR-HL, two BBI trypsin inhibitor peptides with only trypsin inhibitory activity but no antimicrobial activity 
or anti-cancer activity27,28. Besides these peptides, some structurally similar peptides such as Nigroain-A and 
Ranacyclin-T, show broad antimicrobial activity but lack any trypsin inhibitory activity29,30. Interestingly, these 
peptides have highly similar primary structure but distinct bio-functions. Although many structurally similar 
trypsin inhibitor peptides have been found in the past years, until now, none of them showed any anticancer 
Figure 2. (A) Dose-dependent PE-BBI curves for trypsin proteolysis inhibitory assay. The x-axis represents 
time in minutes and the y-axis represents fluorescence intensity. (B) Morrison plots of PE-BBI, the initial rate 
(vi) values at each concentration of PE-BBI (0.1 to 100 µM). RFU/min (relative fluorescence units/min). (C) 
Possible interactions model between bovine trypsin protease and PE-BBI. The active site of trypsin (His58, 
Asp102, and Ser195) and the active site of PE-BBI (Lys9) were performed in stick representation. The disulphide 
bond of PE-BBI was showed in stick representation (Orange).
Figure 3. (A) Dose-response contraction effect of synthetic PE-BBI on rat bladder smooth muscle 
preparations. (B) Dose-response release of PE-BBI on rat-tail artery smooth muscle preparations. Data points in 
each panel represent the mean and SD of values obtained for 5 replicates.
www.nature.com/scientificreports/
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activity28,30–32. Leguminous BBIs have been identified with anti-cancer activity against human prostate, colon, 
breast, and skin cancer cell lines33. According to previous studies, a leguminous BBI showed in vitro and in vivo 
anti-tumour ability and without cytotoxicity in the dimethylhydrazine (DMH) induced colorectal tumour rat 
model4,34. Besides, BG-4, a novel proteinase peptide from Momordica charantia (bitter melon), induced apoptosis 
in HCT-116 and HT-29 colorectal cancer cells20. Another BBI peptide BTCI could form a stable complex with the 
20S proteasome. In the complex form, BTCI can inhibit the trypsin-like proteolytic activity of the 20S proteas-
ome, thereby inducing cytostatic and cytotoxic effects in MCF-7 breast cancer cells by induction of apoptosis35.
In this study, a novel short cyclic peptide PE-BBI was identified from the skin secretions of Pelophylax escu-
lentus. It is the first time a frog skin BBI peptide was found to have the anticancer ability. The primary structure 
of PE-BBI contains the canonical disulphide-bridged loop between Cys6 and Cys16, which has been proved to be 
essential for their trypsin inhibitory capability29. Molecular docking analysis results also suggested that PE-BBI 
inactivates the trypsin proteinase through the combination between its cyclic part (Cys6 ~ Cys16) and the active 
site of trypsin proteinase. Synthetic PE-BBI demonstrated strong trypsin inhibitory activity (Ki = 310 ± 72 nM). 
Besides the proteinase inhibitory activity, it is interesting to see that PE-BBI also has a myotropic activity on iso-
lated rat bladder and rat-tail artery smooth muscle on nano-/subnano-molar concentration. Through MTT assay, 
we also found that PE-BBI has considerable anticancer ability against a range of human colorectal cancer cell lines. 
Meanwhile, PE-BBI did not show any cytotoxicity against the normal human epithelial cell, FHC. Comparing the 
primary structure between PE-BBI and other frog skin-derived proteinase inhibitor peptides (Fig. 6)18,28–30,32, all 
of these peptides contained the same disulphide-bridged loop structure but differ entirely at the N-terminal and 
C-terminal extension amino acid residues. PE-BBI contains more lysine (K) and amidated C-terminal, which 
means PE-BBI has a more positive charge than pLR-HL and HV-BBI. From the previous research findings, we 
noticed that the cancer cell membrane contains more anionic lipids (e.g., phosphatidylserine) than noncancerous 
Figure 4. Dose-dependent anti-cancer activity of PE-BBI, ranging from 1 to 100 µM, against different human 
colorectal cancer cell lines (A) DKS8 (B) DLD-1 (C) HKE3 (D) HCT116 (E) FHC. The IC50 values against four 
cancer cell lines after 24 h incubation, were 50.1 µM, 9.8 µM, 35.4 µM, 50.2 µM, respectively. Meanwhile, PE-
BBI didn’t show any cytotoxicity against human normal endothelial cell lines FHC. Data points in each panel 
represent the mean and SD of values obtained for 9 replicates. Significant differences were marked with asterisks 
(*P < 0.05; **P < 0,01; ***P < 0.001).
www.nature.com/scientificreports/
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cells. Thus, the membrane of cancer cells is negative charged compared to the noncancerous cells. On the surface 
of noncancerous cells, due to zwitterionic phospholipids (e.g. phosphatidylcholine and sphingomyelin) occupies a 
large part, the surface of noncancerous cells is negligible or weak negative charged36. This hypothesis may explain 
why HV-BBI and pLR-HL peptide lack anti-cancer ability, due to the lack of the cell membrane binding capacity.
Regarding the mechanism of anti-cancer cytotoxicity of PE-BBI, several possibilities exist, based on some pre-
vious studies. Some researchers have suggested the anti-cancer ability of BBI is related to the suppression of the 
release of tumourigenesis promoting factors such as the superoxide anion radical and hydrogen peroxide33,37–40. 
Figure 5. Structural characteristics of the protease-inhibitor docking output for PE-BBI and KLKs. The 
secondary structure of PE-BBI was labelled (N-terminal is blue and C-terminal is red), and the active site (Lys9) 
was shown in stick representation. The disulphide bond was showed in stick representation (Orange). The 
active site of KLKs were labelled with arrows and highlight (Yellow). (A) Possible interactions model between 
PE-BBI and KLK4. (B) Possible interactions model between PE-BBI and KLK6. (C) Possible interactions model 
between PE-BBI and KLK8. (D) Possible interactions model between PE-BBI and KLK10.
Figure 6. Comparison of different frog skin derived Bowman-Birk-type trypsin inhibitors18,28–30,32. “-” means 
no effect.
www.nature.com/scientificreports/
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Some other researchers propose that BBIs are able to inhibit some crucial proteolytic processes, which play key 
roles in carcinogenesis31,33,41.
Prognosis/diagnosis value of human tissue kallikrein-related peptidase (KLK) family members have been 
proved in many studies21–24. For instance, KLK4 dysregulation was detected in colon cancer and induced PAR1 
signalling in caner. This study implies KLK4 may represent a novel pathway via PAR1 in colon tumourigenesis42. 
KLK6 mRNA overexpression evokes a poor prognosis in the colon cancer patient cohort43. Moreover, elevated 
KLK8 mRNA and protein level are detected in CRC tissue, which leads to an aggressive phenotype and poor 
prognosis44. The expression level of KLK10 is significantly higher in ovarian, pancreatic and colon cancer com-
pared to normal tissues23,45,46. Previous studies have identified that trypsin and KLK4 shared significant structural 
and sequence similarity, and were both trypsin-like serine proteases. Thus, trypsin inhibitor would be able to 
inhibit KLK4 in addition to trypsin47. Swedberg et al. identified that SFTI-1 had high affinity to KLK447. Thus, 
PE-BBI contains the homology active site region (-TKP1SIPP-) with SFTI-1, which means PE-BBI may represent 
similar affinity to KLK4. The docking results in the present study revealed the active regions of PE-BBI and KLK4 
superimpose extremely well. Moreover, we also tested the binding between PE-BBI and other potential colon 
cancer biomarkers (KLK6, KLK8, and KLK10)23,43–46 and got the similar results as KLK4. The myotropic regula-
tion effect of PE-BBI proved further evidence. KLK family is one of the key regulatory factors of tissue smooth 
muscles by regulating the kallikrein-kinin system48. The inhibition of KLKs would result in smooth muscle con-
traction/release. Thus, PE-BBI might inhibit cancer cell growth by blocking KLK proteins, which also affects the 
kallikrein-kinin system in vivo.
Overall, our study identified a novel multi-functional peptide PE-BBI and assigned its potential anticancer 
mechanism. Compared with leguminous derived BBIs, frog skin-derived BBI peptide PE-BBI has a more con-
served primary structure with smaller molecule size, and is a potential anti-cancer lead compound. Further stud-
ies on the structure–function relationships and mechanisms of the anticancer ability of frog skin-derived BBI 
peptides may provide new candidates for peptide anti-cancer therapies.
Methods and Materials
Materials. Pelophylax esculentus (n = 5) were purchased from a local herpetological supplier. Trifluoroacetic 
acid (TFA), acetonitrile, trypsin from bovine pancreas and trypsin substrate (Gly-Gly-Arg-AMC, Sigma/Aldrich, 
Poole, Dorset, UK). Mueller–Hinton broth (MHB) (Sigma-Aldrich, St. Louis, MO, USA). DLD-1, DKS8, 
HCT116, HKE3 cell lines were cultured in Dulbecco’s Modified Eagle’s Medium F12 (DMEM F12) with 10% 
added FBS and 1% Penicillin-Streptomycin. FHC (ATCC-CRL-1831), and the cells were cultured in DMEM F12 
medium (Gibco, Paisley, UK) containing 10% FBS, 10 ng/mL cholera toxin, 25 mM HEPES, 0.005 mg/mL insu-
lin, 0.005 mg/mL transferrin, 100 ng/mL hydrocortisone, and 1% Penicillin-Streptomycin. DLD-1, HCT116, and 
FHC were supplied by American Type Culture Collection (ATCC, Teddington, Middlesex, UK). DKS8 and HKE3 
were gifts from Prof. Senji Shirasawa’s Laboratory.
Acquisition of Pelophylax esculentus Skin Secretion. The adult frogs (6–8 cm snout to vent length) 
were kept for 4 months prior to secretion harvesting. Transdermal electrical stimulation was used to harvest the 
skin secretions. This technique was first mentioned by Tyler and colleagues in 199249. Briefly, the dorsal skin of 
frogs was stimulated by platinum electrodes (6 V DC; 4 ms pulse-width; 50 Hz) for two times, 20s per duration, 
then chilled deionised water was used to wash and collect the skin secretion before submerging into liquid nitro-
gen for lyophilise. Lyophilisate was stored at −20 °C prior to analysis. All of the above protocols were performed 
under the UK Animal (Scientific Procedures) Act 1986, project licence PPL 2694, issued by the Department of 
Health, Social Services and Public Safety, Northern Ireland. Procedures had been vetted by the IACUC of Queen’s 
University Belfast, and approved on 1 March 2011.
Fractionation of Lyophilised Pelophylax esculentus Skin Secretion by Reverse Phase 
HPLC. The lyophilised skin secretion (5 mg) was dissolved in 0.5 mL of trifluoroacetic acid (TFA)/water 
(0.05/99.95, v/v). Then the solvent was centrifuged to collect the supernatant. The supernatant was analysed by 
using Thermoquest gradient system with an analytical column (Phenomenex C-5; 0.46 cm × 25 cm). The lin-
ear elution gradient (From 0.05/99.95 (v/v) TFA/water to 0.05/19.95/80.0 (v/v/v) TFA/water/acetonitrile) was 
applied to separate the peptides. The flow rate was 1 mL/min. The effluent absorbance was monitored at λ214 nm 
and 1 mL fractions were collected at minute intervals. After 240 minutes, all of the fractions were collected. The 
fractions (240 fractions in total) were separated, lyophilised and stored at −20 °C prior to analysis and screening.
Structural Characterisation of PE-BBI. After trypsin inhibitory screening, fraction #94 which showed 
the highest trypsin inhibitory activity was further applied in the structural characterisation. The molecular 
weight of peptides in fraction #94 was detected by using MALDI-TOF mass spectrometry (Voyager DE instru-
ment, Perspective Biosystems, MA, USA). The peptides with similar molecular weight with those mature pep-
tides obtained from molecular cloning were subjected to LCQ Fleet electrospray ion-trap mass spectrometer 
(Thermo Scientific, San Jose, CA, USA) to clarify their primary structure. Then the mature peptide of PE-BBI was 
chemically-synthesized by solid phase peptide synthesis (SPPS) technology.
Cloning of PE-BBI Precursor-Encoding cDNA. Lyophilised frog skin secretion (5 mg) was lysed 
by mRNA protection buffer by Dynal Biotec, UK. The polyadenylated mRNA was isolated by using magnetic 
oligo-dT beads as described by the manufacturer (Dynal Biotec, UK). To obtain the completed full-length trypsin 
inhibitor precursor encoding region, 5′- and 3′-rapid amplification of cDNA ends (RACE) procedures were 
applied using a SMART-RACE kit (Clontech, UK) followed manufacturer protocol50.
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Antimicrobial Assay. Gram-negative bacteria Escherichia coli (NCTC 10418); Gram-positive bacteria 
Staphylococcus aureus (NCTC 10788) and pathogenic yeast Candida albicans (NCYC 1467) were used in min-
imum inhibitory concentration (MIC) assays to investigate the board antimicrobial activity ability of synthetic 
PE-BBI. Microorganisms involved in MIC assays were cultured in MHB for 16–18 h. Then sub-cultured for 2~4 h 
to allow the microorganism to enter the logarithmic growth phase. Subsequently, proper density of bacterial 
(1 × 106 colony forming units (cfu)/mL) and fungi (1 × 105 cfu/mL) were seeded into 96 well plate. Different 
concentration ranged from 1 to 512 μM of PE-BBI were added into each well (6 replicates per concentration). The 
absorbance value at 550 nm was detected using a Synergy HT plate reader (Biotech, Minneapolis, MN, USA) after 
18 h incubation in 37 °C incubator50.
Myotropic Assay of PE-BBI. Female Wistar rats (250–300 g) were applied in this study and sacrificed fol-
lowed the principle of institutional animal experimentation ethics and UK animal research guidelines. All of the 
procedures involved in this study was approved by IACUC of Queen’s University Belfast. Rat-tail artery and blad-
der were isolated and located in pre-chilled Kreb’s solution equilibrated with 95% O2, 5% CO251. Isolated muscle 
strips (2–10 mm) were vertically suspended in a 2 mL organ bath containing 37 °C Kreb’s solution. The Kreb’s 
solution was constant refreshing by constant flowing (2 mL/min) during the assay. Potassium chloride (KCL, 
60 mM) was used to test for viability of muscle strips after 20 min equilibration. After the smooth muscle strip 
were prepared, the synthetic replicates of PE-BBI (10−11 to 10−5 M) was used to quantify the myogenic potency 
on rat-tail artery and bladder smooth muscle. Between each concentration, the smooth muscle strip was washed 
5 mins and re-equilibration for another 5 min. Each data point was repeated on at least five independent muscle 
strips. The tension change was amplified and recorded by a PowerLab System (AD Instruments Pty Ltd.)51.
Trypsin Inhibitor Assay of PE-BBITrypsin (0.1 µM in 1 mM HCL) and trypsin substrate (50 µM) were pre-
pared prior to the assay. Trypsin inhibitory assay included positive group (10 µL trypsin, 180 µL substrate, 20 µL 
PBS), experiment group (10 µL trypsin, 180 µL substrate, 20 µL PE-BBI ranging from 0.1–100 µM) and control 
group (180 µL substrate, 30 µL PBS). In each well, the final volume was 210 µL. After 8 mins incubation, the fluo-
rescent strength released from substrate hydrolysis was monitored continuously at 460 nm (excitation at 360 nm) 
in a CYTOFLUOR® multi-well plate reader Series 4000 spectrofluorometer. Each sample was carried out in trip-
licate and repeated at least three times. The fluorescent strength values were used to calculate the initial rate (vi) 
and inhibition constants (Ki)32.
MTT Assay of PE-BBI. Synthetic replicates of PE-BBI were screened on the human colon cancer cell lines, 
DLD-1, DKS8, HCT116, and HKE3. Human colon endothelial cell FHC was used to evaluate the cytotoxicity of 
synthetic peptides on normal human cell line. All the cell lines were seeded with 5000 cells/well in 96 well plate. 
The seeded cells were incubated for 24 h and further starved for 12 h in prior of experiment, a series of PE-BBI 
concentrations (10−7–10−4 M) were prepared in related growth medium and added in the experiment group with 
6 replicates. The same volume of PBS was added in the control group. After 24 h PE-BBI treatment, MTT assay 
was used followed the protocol described in detail previously52. Briefly, 10 µL of MTT (5 mg/mL) was added 
and incubated for 4 h. Then the supernatant was removed and 100 µL of DMSO was added to dissolve the pur-
ple formazan generated by live cells. The absorbance was measured at 570 nm by using EL808 TM Absorbance 
Microplate Reader (Biolise BioTek EL808, Winooski, VT, USA). The cell viability (%) of each concentrations were 
calculated by normalized to the control, respectively.
Molecular Docking Simulation Analysis. Molecular docking simulation of PE-BBI and trypsin protein-
ase was carried out using BIOVIA Discovery Studio 2017 R2 (Biovia, San Diego, CA, USA). The purpose of 
molecular docking was simulated the predominant binding condition(s) between ligand peptide (PE-BBI) and 
receptor proteins (KLK family members) with known three-dimensional structure. The three-dimensional (3D) 
structure of bovine trypsin (PDB ID: 2O9Q), KLK4 (PDB ID: 4K8Y), KLK6 (PDB ID: 3VFE), KLK8 (PDB ID: 
5MS4), and KLK10 (PDB ID: 5LPE) were obtained from the Protein Data Bank (https://www.rcsb.org/). Before 
docking, interior water molecules and ligands should be deleted to clear the docking candidates. The defaulted 
hided hydrogen atoms were added to both proteins. Subsequently, we used ZDock53, a rigid-body docking algo-
rithm, to create the initial docking poses between PE-BBI and trypsin, KLK4, KLK6, KLK8, and KLK10. We 
applied the protocol with parameters as following: Angular Step Size as 15; RMSD cutoff as 6.0; Interface Cutoff 
as 9.0; Maximum Number of Clusters as 60. The ZDock protocol generated lots of docking poses ranked by the 
ZDock score. ZDock score was based on shape complementary to evaluate the reliability of docking poses. The 
top ranked poses were classified into different clusters54,55, and further refined by RDock56. RDock applied the 
Chemistry at Harvard Macromolecular Mechanics (CHARMm) force field to generate the energy minimized 
docking models. In this study, the top ranked ZDock poses were optimized by RDock then further applied in the 
molecular docking57.
Statistical Analysis. Statistical analysis was performed using GraphPad Prism 6 software. P values were cal-
culated by Student’s t-test from the mean values of the indicated data. Significant differences were demonstrated 
with asterisks (*P < 0.05; **P < 0,01; ***P < 0.001).
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